Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
5e5 of anti-Carbonic Anhydrase IX CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Carbonic Anhydrase IX (38-414) Protein, His Tag (Cat. No. CA9-HA2H7) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
2e5 of Anti-Carbonic Anhydrase IX CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human Carbonic Anhydrase IX (38-414), His Tag (Cat. No. CA9-HF228) and negative control protein respectively. FITC signal was used to evaluate the binding activity (QC tested).
Immobilized Anti-Carbonic Anhydrase IX Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human Carbonic Anhydrase IX (38-414), His Tag (Cat. No. CA9-HF228) with a linear range of 0.01-1.25 μg/mL (QC tested).
The purity of Cynomolgus Carbonic Anhydrase IX Protein, His Tag (Cat. No. CA9-C52H3) is more than 90% and the molecular weight of this protein is around 38-48 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Girentuximab-Zr-89 | TLX-250-CDx; 89Zr-TX-250; TLX250-CDx; 89Zr-TX250 | Phase 3 Clinical | Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Sarcoma; Cholangiocarcinoma; Contrast agents; Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms | Details | |
Lutetium-177 DOTA girentuximab | TLX-250 | Phase 2 Clinical | Heidelberg, Telix Pharmaceuticals Ltd | Solid tumours; Carcinoma, Renal Cell; Neoplasms | Details |
[177Lu]Lu-DPI-4452 | [177Lu]Lu-DPI-4452 | Phase 2 Clinical | Debiopharm International Sa | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Debio-0328 | [68Ga]Ga-DPI-4452; Gallium-68-DPI-4452 | Phase 2 Clinical | Debiopharm International Sa | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
PMI-05 | PMI-05 | Phase 1 Clinical | Precision Molecular Inc | Neoplasms | Details |
Girentuximab | MAb-G250; cG250; WX-G250 | Phase 1 Clinical | Kidney Neoplasms; Carcinoma, Renal Cell | Details | |
PHC-102 | PHC102; 99mTc-CAIX | Phase 1 Clinical | Philochem | Carcinoma, Renal Cell | Details |
Indium-111-DOTA-girentuximab-IRDye800CW (Radboud University) | Phase 1 Clinical | Radboud University Nijmegen | Carcinoma, Renal Cell; Diagnostic agents | Details | |
CA9hu-1 | CA9hu-1 | Phase 1 Clinical | Mabpro AS | Head and Neck Neoplasms; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
Sulfamide-nitroimidazole | Clinical | Dualtpharma | Neoplasms | Details | |
Girentuximab-Zr-89 | TLX-250-CDx; 89Zr-TX-250; TLX250-CDx; 89Zr-TX250 | Phase 3 Clinical | Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Sarcoma; Cholangiocarcinoma; Contrast agents; Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms | Details | |
Lutetium-177 DOTA girentuximab | TLX-250 | Phase 2 Clinical | Heidelberg, Telix Pharmaceuticals Ltd | Solid tumours; Carcinoma, Renal Cell; Neoplasms | Details |
[177Lu]Lu-DPI-4452 | [177Lu]Lu-DPI-4452 | Phase 2 Clinical | Debiopharm International Sa | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Debio-0328 | [68Ga]Ga-DPI-4452; Gallium-68-DPI-4452 | Phase 2 Clinical | Debiopharm International Sa | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
PMI-05 | PMI-05 | Phase 1 Clinical | Precision Molecular Inc | Neoplasms | Details |
Girentuximab | MAb-G250; cG250; WX-G250 | Phase 1 Clinical | Kidney Neoplasms; Carcinoma, Renal Cell | Details | |
PHC-102 | PHC102; 99mTc-CAIX | Phase 1 Clinical | Philochem | Carcinoma, Renal Cell | Details |
Indium-111-DOTA-girentuximab-IRDye800CW (Radboud University) | Phase 1 Clinical | Radboud University Nijmegen | Carcinoma, Renal Cell; Diagnostic agents | Details | |
CA9hu-1 | CA9hu-1 | Phase 1 Clinical | Mabpro AS | Head and Neck Neoplasms; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
Sulfamide-nitroimidazole | Clinical | Dualtpharma | Neoplasms | Details |
This web search service is supported by Google Inc.